Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Clinical trial NCT07092202 · RECRUITING

Trial details

NCT number: NCT07092202
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Leptomeningeal Metastasis NSCLC Intrathecal Chemotherapy Tyrosine Kinase Inhibitor

Start date: 2025-04-15
Primary completion: 2027-05-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.